RxDoctor Payments Data

Hailey Lankford, PA

Medical · Anchorage, AKNPI 1477035376

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,394 of the $2,851 with a category attached, or 84.0%. 16 manufacturers reported payments, led by Medtronic at 28.4% of the total.

$2,851in general payments, 2019–2025

Across 101 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$810
  • Abbott$799
  • AbbVie$475
  • Collegium Pharmaceutical, Inc.$181
  • Nevro Corp.$116
  • Ipsen Biopharmaceuticals, Inc$91
  • plus $380 from 10 others

What the payments were for

  • Travel & lodging$45716%
  • Food & beverage$2,39484%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,851 in reported general payments places this provider in the 85th percentile of 140 medical providers in Alaska.

See all medical providers in Alaska

Medicare billing

Part B allowed, 2024
$103,865
Medicare patients
252
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl36$26,651
Buprenorphine73$21,575
Diclofenac Sodium21$4,727
Lidocaine55$4,105
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen188$4,011
OxycontinOxycodone Hcl11$3,148
Oxycodone Hcl94$2,828
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen78$2,438
Pregabalin67$2,024
Gabapentin137$1,953
Celecoxib47$793
Cyclobenzaprine Hcl90$681
Tizanidine Hcl72$548
Duloxetine Hcl47$463
Baclofen29$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$181$26,65136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 140 medical providers in Alaska.

Other medical in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →